A. Sanchez-alcaraz et al., Therapeutic drug monitoring of tobramycin: once-daily versus twice-daily dosage schedules, J CLIN PH T, 23(5), 1998, pp. 367-373
Objective: To evaluate the effect of dosage regimen (once-daily vs. twice-d
aily) of tobramicyn on steady-state serum concentrations and toxicity.
Materials and methods: Patients undergoing treatment with iv tobramycin (4
mg/kg/day) were randomised to two groups. Group OD (rr = 22) received a onc
e-daily dose of tobramycin and group TD (rt; 21) received the same dose div
ided into two doses daily. Tobramycin serum concentrations (peak and trough
) were measured by enzyme multiplied immunoassay. The renal and auditorory
functions of the patients were monitored before, during and immediately aft
er treatment.
Results: The two groups were comparable with respect to sex, age, body weig
ht and renal function. No statistically significant differences were found
in mean daily dose, duration of treatment, or cumulative dose. Trough conce
ntrations were <2 mu g/ml in the two groups (100%). Peak concentrations wer
e >6 mu g/ml in 100% of the OD group and in 67% of the TD group (P< 0.01).
Mean peak concentrations were markedly different: 11.00+/-2.89 mu g/ml in O
D vs. 6.53 +/- 1.45 mu g/ml in TD (P< 0.01). The pharmacokinetics parameter
s were: K-er (0.15 +/- 0.03/h in OD vs. 0.24 +/- 0.06/h in TD), t(1/2), (4.
95 +/- 1.41 h in OD vs. 3.07 +/- 0.71 h in TD), V-d (0.35 +/- 0.11 1/kg in
OD vs. 0.33 +/- 0.09 l/kg in TD), Cl (0.86 +/- 0.29 ml/min/kg in OD vs. 1.2
8 +/- 0.33 ml/min/kg in TD). Increased serum creatinine was observed in 73%
of patients in OD versus 57% of patients in TD, without evidence of nephro
toxicity. In TD group, three patients developed decreased auditory function
, of which one presented with an auditory loss of -30 db, whereas in the OD
group only one patient presented decreased auditory function.
Conclusion: This small study suggests that a once-daily dosing regimen of t
obramycin is at least as effective as and Is no more and possibly less toxi
c than the twice-daily regimen. Using a single-dose therapy peak concentrat
ion determination is not necessary, only trough samples should be monitored
to ensure levels below 2 mu g/ml.